Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.37 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895714 | 0.84 | TP53 (0.47) | KDRKARS1NPC1RAB9ANFKB1 | |
| SCHEMBL4900760 | 0.82 | KARS1 (0.40) | KDRACHECTSCKARS1NPC1 | |
| SCHEMBL4899168 | 0.81 | KARS1 (0.43) | KDRCTSCKARS1NPC1RAB9A | |
| SCHEMBL4892301 | 0.80 | SLC2A1 (0.44) | KDRNPC1RAB9ANFKB1NFKB2 | |
| SCHEMBL4901742 | 0.80 | SYK (0.40) | KDR | |
| SCHEMBL4904851 | 0.79 | KMT2A (0.48) | KDRKARS1NPC1RAB9ANFKB1 | |
| SCHEMBL4904404 | 0.76 | PDPK1 (0.45) | KDRCTSCKARS1NPC1RAB9A | |
| SCHEMBL4894249 | 0.76 | NPC1 (0.48) | NPC1RAB9ANFKB1NFKB2RELA | |
| Hydrochloric Acid SCHEMBL4902556 | 0.76 | PDPK1 (0.44) | KDRCTSCKARS1NPC1RAB9A | |
| SCHEMBL14234652 | 0.75 | MEN1 (0.60) | KARS1NPC1RAB9ANFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108600-A1 | Polycyclic Pyridines as Potassium Ion Channel Modulators | ICAGEN, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1737852-A2 | POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS | Icagen, Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100349-A2 | POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108600-A1 | Polycyclic Pyridines as Potassium Ion Channel Modulators | KCNJ2, KCNH2, KCNQ1 | KDR 3367/4885ACHE 2058/4885CTSC 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.